| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
TuHURA Biosciences (NASDAQ:HURA) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of ...
Company anticipates initiating its Phase 3 accelerated approval trial of IFx-Hu2.0 as adjunctive therapy with Keytruda® (pembro...